Managing Director, Healthcare at Safeguard Scientifics
Venture Capital/Private Equity
Gary is responsible for identifying, deploying capital in and supporting emerging healthcare companies in diagnostics, medical devices and healthcare IT. Gary is currently a board member of Safeguard partner companies Dabo Health, Good Start Genetics, Medivo, Quantia, Propeller Health, Syapse and Trice Medical and recently realized successful exits with partner companies Advanced BioHealing, Alverix, Avid, Radiopharmaceuticals, Crescendo Biosciences and NuPathe to strategic acquires Shire, Becton Dickinson, Eli Lilly, Myriad, and Teva, respectively. Gary joined Safeguard from BioAdvance, a state initiative committed to funding early-stage life sciences companies, where he served as Managing Director and Chief Operating Officer. Previously, he was Chief Executive Officer at Pluvita Corporation, a company developing personalized medicine solutions and served as Chief Operating Officer at Genovo, and head of research & development at Avigen, both development stage gene therapy companies. Gary received his MD degree from Washington University, trained in internal medicine at Barnes Hospital in St. Louis, MO, and completed hematology sub-specialty training at Stanford. Gary currently involves himself with a number of entrepreneurs and entrepreneurial activities and is currently a lecturer in the Health Care Systems Department at the Wharton School at the University of Pennsylvania where he teaches an interdisciplinary graduate level course in healthcare entrepreneurship.